Stocks

Abbott has a potential to gain. What about Gilead Sciences?

Most of the stocks collapsed due to the coronavirus epidemic, as the businesses were suspended during all the countries’ lockdowns. However, there are several stocks which gained during the pandemic due to their special niche. Such are medicine and tech stocks, for example, as well as internet stocks.

Abbott Laboratories has real potential and resources to make a difference. The company’s tests to identify the coronavirus have helped healthcare providers make significant headway in the fight against the pandemic.

Labs throughout the U.S. are already using Abbott’s molecular test. And the FDA granted Abbot an emergency use authorization (EUA) for a rapid coronavirus testing system on April 3. The new product can ascertain results much faster than any other available COVID-19 test. It detects positive results in five minutes and negative results in 13 minutes.

Analyst Kristen Stewart noted that all the medical facilities and physician offices would need these tests, and pricing will probably be in the $35-$45 range per test. This means that Abbott will gain significantly over the coming months.

Related Post

According to reports, 4 million of Abbott’s molecular tests can be conducted each month on its m2000 systems, with the company charging about $30 per test. Stewart set the price target at $98 for this stock.  Investors will gain 23% over the year with this target.

What are the experts’ estimates about Gilead Sciences?

Gilead Sciences is another biotech stock, which made a great headway due to the coronavirus outbreak. The company works on its experimental COVID-19 treatment currently. It announced recently about plans to donate 1.5 million doses of the new drug, which could treat 140,000 patients.

Furthermore, Gilead Sciences’ shares rose by 20% year-to-date. This gained Wall Streets’ attention due to the new medicine. Analyst Jeffries’ Michael Yee believes that the stock will hit a high again. He set a price target at $89 for the stock, indicating a 14% upside potential.

Recent Posts

US Economy Growth Slows to 1.6% in First Quarter

Key Points: US economy growth slowed to 1.6% in Q1, below the expected 2.4%. Consumer spending growth tapered, but business…

1 day ago

Microsoft Revenue Hits $61.9B, Up 17% Year-Over-Year

Key Points: Microsoft's რevenue surged to $61.9 billion, a 17% increase driven by robust sales in all business segments. Notable…

1 day ago

Ethereum Stabilizes Below $3,180 Amid Market Caution

Key Points Ethereum is Trading below $3,180, under the 100-hourly SMA, indicating a cautious market trend despite the formation of…

1 day ago

Oil Prices Up: Brent Gains 2%, WTI Increases 0.5%

Key Points Oil Prices rose, Brent crude oil reached $89.32 per barrel, up 2%, and WTI at $83.86, up 0.5%.…

1 day ago

GBP/USD Drops to 1.2502 Amid Economic Turmoil

Key Points GBP/USD is currently at 1.2502, impacted by UK-US economic turbulence and monetary policies. US Q1 GDP growth at…

1 day ago

USD/INR Emerges as Steadiest Major Currency

Key Points: Despite global volatility, USD/INR is the least volatile major currency in FY 2023-24, supported by interbank USD sales…

2 days ago

This website uses cookies.